The Cancer Letter

Inside information on cancer research and drug development

Funding Opportunities

DOD Prostate Cancer Research Program opportunities

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The FY18 Defense Appropriations Act provides $100 million to the Department of Defense Prostate Cancer Research Program to support innovative, high-impact prostate cancer research.

FY18 PCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.

Applications submitted to the FY18 PCRP must addresses one or more of the Overarching Challenges (revised for FY18):

  • Develop treatments that improve outcomes for men with lethal prostate cancer

  • Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations

  • Define the biology of lethal prostate cancer to reduce death

  • Improve the quality of life for survivors of prostate cancer

http://cdmrp.army.mil/funding/pcrp

Health Disparity Research Award

Letter of Intent due Sept. 20

Health Disparity Scholar Award

Letter of Intent due Sept. 20

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal at https://eBRAP.org prior to the pre-application deadline.

All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.

Table of Contents

YOU MAY BE INTERESTED IN

Obituary

Felix Feng, GU cancer researcher who made fundamental discoveries in genomics, dies at 48

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
By Melinda Krigel
Obituary

Feng’s team advanced the understanding of biomarkers in prostate cancer

The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.
By NRG Staff
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account